Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study
| Autor: | Susanne Jentsch, Martin Hammer, Gabriele E. Lang, Dietrich Schweitzer, Jürgen Strobel, Jens Dawczynski |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
Lutein medicine.medical_specialty Visual acuity genetic structures Dose Visual Acuity Ascorbic Acid Xanthophylls Placebo Antioxidants law.invention Cellular and Molecular Neuroscience chemistry.chemical_compound Double-Blind Method Randomized controlled trial Zeaxanthins law Geographic Atrophy Ophthalmology Fatty Acids Omega-3 Humans Vitamin E Medicine Prospective Studies Prospective cohort study Aged business.industry Middle Aged Macular degeneration medicine.disease eye diseases Sensory Systems Zeaxanthin Drug Combinations chemistry Zinc Compounds Dietary Supplements Female sense organs medicine.symptom business Retinal Pigments Follow-Up Studies |
| Zdroj: | Graefe's Archive for Clinical and Experimental Ophthalmology. 251:2711-2723 |
| ISSN: | 1435-702X 0721-832X |
| DOI: | 10.1007/s00417-013-2376-6 |
| Popis: | The primary objective of LUTEGA is to determine the long-term effect of a supplementation with fixed combination of lutein, zeaxanthin, omega-3-longchain-polyunsaturated-fatty-acids (O-3-LCPUFAs) and antioxidants on macular pigment optical density (MPOD) in patients with non-exudative age-related macular degeneration (AMD). The LUTEGA study is a double-blind, placebo-controlled clinical trial. 172 patients with non-exudative AMD were enrolled and randomized to three treatment arms. Supplementation included either once (dosage D1) or twice daily (dosage D2) of 10 mg L / 1 mg Z/ O-3-LCPUFAs (thereof 100 mg DHA, 30 mg EPA)/ antioxidants, or placebo (P). After best-corrected visual acuity (BCVA) test, blood sample was collected and MPOD was measured using the 1-wavelength-reflection method and recording reflection images at 480 nm (modified VisucamNM/FA, Carl Zeiss Meditec, Germany). During 1 year of intervention, AMD patients were followed up after 1, 3, 6 and 12 months. 145 AMD patients (D1 = 50, D2 = 55, P = 40) completed the study. After 12 months of intervention, the MPOD parameters (volume, area, maxOD, meanOD) increased significantly in treatment arms D1 and D2 (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink